Medicare Negotiation Workarounds: Lilly’s Ricks On Big Pharma Strategies For Small Molecule Drugs
A vocal critic of the way Medicare price negotiation program treats small molecule drugs, the Lilly CEO and offers possible scenarios of how developers may react.
You may also be interested in...
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
Eli Lilly & Co. CEO David Ricks highlighted how Medicare drug price negotiation policies are already impacting R&D investment during a J.P. Morgan investor call.
‘It takes longer than nine years’ to profit from small molecule drug R&D, company CEO maintains in arguments against the negotiation process, and its timelines, in the Senate drug pricing reform legislation.